Phenotypes associated with this allele

• Allele Symbol: Card11^m1Btlr
• Allele Name: mutation 1, Bruce Beutler
• Allele ID: MGI:3805728
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Card11^m1Btlr/Card11^m1Btlr	C57BL/6J-Card11^m1Btlr	MGI:3808003

Genotype
MGI:3808003

hm1

• Allelic Composition: Card11^m1Btlr/Card11^m1Btlr
• Genetic Background: C57BL/6J-Card11^m1Btlr

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

immune system phenotype ( J:139069 )

N • antigen presentation by CD8⁺ T cells is normal

N • upregulation of CD69 and CD44 by mutant T cells in response to treatment with TCR-crosslinking antibodies is only slightly impaired (nearly normal)

N • numbers and proportions of macrophages and neutrophils are normal

N • dendritic cell (DC) numbers and proportions appear normal; cross-priming by DCs is normal, and DCs from mutant mice upregulate costimulatory molecules (CD40, CD80, CD86, MHC class I and II) normally upon stimulation by apoptotic cells or toll-like receptor (TLR) ligands

decreased B cell proliferation ( J:139069 , J:149767 )

• mutant mice exhibit impaired B cell proliferation after immunization with ovalbumin in Freund's complete adjuvant (J:139069)

abnormal double-negative T cell morphology ( J:139069 , J:149767 )

• the double-negative thymocyte populations are shifted to the DN4 stage (J:139069)

decreased mature B cell number ( J:139069 , J:149767 )

decreased B-1 B cell number ( J:139069 , J:149767 )

• peritoneal B1 cell numbers are reduced (J:139069)

decreased NK cell number ( J:139069 , J:149767 )

decreased NK T cell number ( J:139069 , J:149767 )

decreased gamma-delta T cell number ( J:139069 , J:149767 )

decreased memory T cell number ( J:139069 , J:149767 )

• the numbers and proportions of memory CD4⁺ T cells are reduced (J:139069)

decreased regulatory T cell number ( J:149767 )

• regulatory T cells are absent in the thymus and have a ten-fold reduction in the periphery

• regulatory T cells in the periphery greatly expand in response to MCMV infection

abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology ( J:149767 )

• regulatory T cells fail to develop when mutant bone marrow is transferred to wild-type mice suggesting defect is intrinsic to hematopoietic pre-cursors

• in vitro, less activated CD4⁺ T cells express the regulatory marker FoxP3

decreased immunoglobulin level ( J:139069 )

• reduced basal serum immunoglobulin levels (IgM, IgG1, IgG2a, IgG2b, IgG3)

• mutant mice fail to mount antigen-specific IgM and IgG responses after immunization with ovalbumin in Freund's complete adjuvant

decreased IgG1 level ( J:139069 , J:149767 )

• decreases are greater than 1 log unit (J:149767)

decreased IgG2a level ( J:139069 , J:149767 )

• decreases are greater than 1 log unit (J:149767)

decreased IgG2b level ( J:139069 , J:149767 )

• decreases are greater than 1 log unit (J:149767)

decreased IgG2c level ( J:149767 )

decreased IgG3 level ( J:139069 , J:149767 )

• decreases are greater than 1 log unit (J:149767)

decreased IgM level ( J:139069 , J:149767 )

• decreases are greater than 2 log units (J:149767)

abnormal NK cell physiology ( J:139069 )

• mutant mice fail to kill syngeneic class I MHC-deficient cells (NK cell-specific target cells) injected a week after primary immunization with irradiated ovalbumin (OVA)-expressing cells

abnormal cytotoxic T cell physiology ( J:139069 )

• mutant mice immunized with irradiated ovalbumin (OVA) expressing cells fail to kill OVA (specific antigen) expressing target C57BL/6J splenocytes injected a week later

abnormal T cell activation ( J:139069 )

• in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28), mutant T cells fail to upregulate CD25 (IL-2Ralpha chain), indicating impairment of TCR-mediated T cell activation

decreased T cell proliferation ( J:139069 , J:149767 )

• in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28), mutant T cells fail to proliferate, indicating impairment of the TCR-mediated T cell proliferation response; the proliferation defect can be partially rescued by IL-2 treatment of mutant T cells (J:139069)

• in vitro-expanded CD8⁺ T cells isolated from mutant mice a week after their immunization with irradiated ovalbumin (OVA) expressing cells fail to undergo secondary expansion upon restimulation (J:139069)

abnormal cytokine secretion ( J:149767 )

• while present in reduced numbers, TGF-beta secretion is enhanced in regulatory T cells

decreased interferon-gamma secretion ( J:139069 )

• in vitro-expanded CD8⁺ T cells isolated from mutant mice a week after their immunization with irradiated ovalbumin (OVA) expressing cells fail to produce interferon (IFN) gamma upon restimulation

decreased interleukin-2 secretion ( J:139069 )

• mutant T cells do not produce interleukin 2 (IL-2) in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28)

dermatitis ( J:139069 , J:149767 )

• at 4-5 months of age, mutant mice have ~50% incidence of severe dermatitis (J:139069)

• some mice develop severe dermatitis with age (J:149767)

hematopoietic system

decreased B cell proliferation ( J:139069 , J:149767 )

• mutant mice exhibit impaired B cell proliferation after immunization with ovalbumin in Freund's complete adjuvant (J:139069)

abnormal double-negative T cell morphology ( J:139069 , J:149767 )

• the double-negative thymocyte populations are shifted to the DN4 stage (J:139069)

decreased mature B cell number ( J:139069 , J:149767 )

decreased B-1 B cell number ( J:139069 , J:149767 )

• peritoneal B1 cell numbers are reduced (J:139069)

decreased NK cell number ( J:139069 , J:149767 )

decreased NK T cell number ( J:139069 , J:149767 )

decreased gamma-delta T cell number ( J:139069 , J:149767 )

decreased memory T cell number ( J:139069 , J:149767 )

• the numbers and proportions of memory CD4⁺ T cells are reduced (J:139069)

decreased regulatory T cell number ( J:149767 )

• regulatory T cells are absent in the thymus and have a ten-fold reduction in the periphery

• regulatory T cells in the periphery greatly expand in response to MCMV infection

abnormal CD4-positive, CD25-positive, alpha-beta regulatory T cell morphology ( J:149767 )

• regulatory T cells fail to develop when mutant bone marrow is transferred to wild-type mice suggesting defect is intrinsic to hematopoietic pre-cursors

• in vitro, less activated CD4⁺ T cells express the regulatory marker FoxP3

decreased immunoglobulin level ( J:139069 )

• reduced basal serum immunoglobulin levels (IgM, IgG1, IgG2a, IgG2b, IgG3)

• mutant mice fail to mount antigen-specific IgM and IgG responses after immunization with ovalbumin in Freund's complete adjuvant

decreased IgG1 level ( J:139069 , J:149767 )

• decreases are greater than 1 log unit (J:149767)

decreased IgG2a level ( J:139069 , J:149767 )

• decreases are greater than 1 log unit (J:149767)

decreased IgG2b level ( J:139069 , J:149767 )

• decreases are greater than 1 log unit (J:149767)

decreased IgG2c level ( J:149767 )

decreased IgG3 level ( J:139069 , J:149767 )

• decreases are greater than 1 log unit (J:149767)

decreased IgM level ( J:139069 , J:149767 )

• decreases are greater than 2 log units (J:149767)

abnormal NK cell physiology ( J:139069 )

• mutant mice fail to kill syngeneic class I MHC-deficient cells (NK cell-specific target cells) injected a week after primary immunization with irradiated ovalbumin (OVA)-expressing cells

abnormal cytotoxic T cell physiology ( J:139069 )

• mutant mice immunized with irradiated ovalbumin (OVA) expressing cells fail to kill OVA (specific antigen) expressing target C57BL/6J splenocytes injected a week later

abnormal T cell activation ( J:139069 )

• in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28), mutant T cells fail to upregulate CD25 (IL-2Ralpha chain), indicating impairment of TCR-mediated T cell activation

decreased T cell proliferation ( J:139069 , J:149767 )

• in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28), mutant T cells fail to proliferate, indicating impairment of the TCR-mediated T cell proliferation response; the proliferation defect can be partially rescued by IL-2 treatment of mutant T cells (J:139069)

• in vitro-expanded CD8⁺ T cells isolated from mutant mice a week after their immunization with irradiated ovalbumin (OVA) expressing cells fail to undergo secondary expansion upon restimulation (J:139069)

integument

dermatitis ( J:139069 , J:149767 )

• at 4-5 months of age, mutant mice have ~50% incidence of severe dermatitis (J:139069)

• some mice develop severe dermatitis with age (J:149767)

cellular

decreased B cell proliferation ( J:139069 , J:149767 )

• mutant mice exhibit impaired B cell proliferation after immunization with ovalbumin in Freund's complete adjuvant (J:139069)

decreased T cell proliferation ( J:139069 , J:149767 )

• in response to treatment with TCR-crosslinking antibodies (alpha-CD3/28), mutant T cells fail to proliferate, indicating impairment of the TCR-mediated T cell proliferation response; the proliferation defect can be partially rescued by IL-2 treatment of mutant T cells (J:139069)

• in vitro-expanded CD8⁺ T cells isolated from mutant mice a week after their immunization with irradiated ovalbumin (OVA) expressing cells fail to undergo secondary expansion upon restimulation (J:139069)